NCT03381430 2017-12-22
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Qilu Pharmaceutical Co., Ltd.
Phase NA Unknown
Qilu Pharmaceutical Co., Ltd.
Assistance Publique - Hôpitaux de Paris
H. Lee Moffitt Cancer Center and Research Institute